Acquired Hemophilia Treatment Market 2018: Key Players Included Baxalta Inc, Baxter Healthcare Corporation, Bristol-Myers Squibb, Genentech Inc. – Credence Research

Credence Research Logo
According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII.

The latest market report published by Credence Research, Inc. “Global Acquired Hemophilia Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023,” the acquired hemophilia treatment market was valued at USD 1,923.4 Mn in 2015, and is expected to reach USD 2,474.7 Mn by 2023, expanding at a CAGR of 3.2% from 2016 to 2023.

Browse the full report Acquired Hemophilia Treatment Market – Growth, Future Prospects, Competitive Analysis, 2016 – 2023 at http://www.credenceresearch.com/report/acquired-hemophilia-treatment-market

Market Insights

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners suggest that, acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50% no cause is known i.e. idiopathic. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes.

Based on the type of therapeutics, the acquired hemophilia treatment market is segmented into:

  • Traditional Therapies
    • Steroid Treatment
    • Cytotoxic Treatment
    • Immunomodulatory Treatment
  • Advanced Therapies
    • Desmopressin
    • Recombinant Activated Factor VII/NovoSeven
    • Recombinant Activated Factor VIII/Obizur
    • Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. The acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies.

Request for customization research report @ http://www.credenceresearch.com/request-for-customization/57894

Chapter 1 Preface 8 
1.1 Report Description 8 
1.1.1 Purpose of the Report 8 
1.1.2 Target Audience 8 
1.1.3 USP and Key Offerings 8 
1.2 Research Scope 9 
1.3 Research Methodology 10 
1.3.1 Phase I – Secondary Research 10 
1.3.2 Phase II – Primary Research 11 
1.3.3 Phase III – Expert Panel Review 11 
1.3.4 Assumptions 12

Chapter 2 Executive Summary 13 
2.1 Acquired Hemophilia Treatment Market Portraiture 13 
2.2 Acquired Hemophilia Treatment Market, by Therapeutic Type, 2015 (US$ Mn) 14 
2.3 Acquired Hemophilia Treatment Market, by Geography, 2015 (Value %) 15

Chapter 3 Global Acquired Hemophilia Treatment Market Analysis 16 
3.1 Global Acquired Hemophilia Treatment Market Overview 16 
3.2 Prevalence of Acquired Hemophilia 17 
3.3 Market Dynamics 18 
3.3.1 Market Drivers 18 
3.3.1.1 Rise in Geriatric Population 18 
3.3.1.2 Growing Demand for Prophylaxis Strategies 19 
3.3.2 Challenges 20 …

Chapter 6 Company Profiles 42 
6.1 Baxalta, Inc 42 
6.2 Baxter Healthcare Corporation 43 
6.3 Bristol-Myers Squibb 44 
6.4 Genentech, Inc. 45 
6.5 Novo Nordisk A/S 46 
6.6 Ferring B.V. 47 
6.7 Sanofi SA 49

Download sample research report @ http://www.credenceresearch.com/sample-request/57894

For the purpose of this study, the global acquired hemophilia treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Acquired Hemophilia Treatment

North America was observed as the largest market for acquired hemophilia treatment in the base year 2015. Constituted by regional markets of U.S. and Canada; North America is the clear leader in the global acquired hemophilia treatment market. North America dominated the market due to aging population, supportive government policies, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. In developed countries of U.S. and Canada, the network of hemophilia care centers is well set with domestic government support. The primary management option is evolved in developed countries with early treatment of bleeding episodes and quick home therapy. 

Related Reports :

http://www.credenceresearch.com/report/non-alcoholic-concentrated-syrup-market

http://www.credenceresearch.com/report/specialty-milk-formula-market

Media Contact
Company Name: Credence Research, Inc
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Phone: +1-800-361-8290
Address:105 N 1st ST #429, SAN JOSE, CA 95103 US
City: SAN JOSE
State: California
Country: United States
Website: http://www.credenceresearch.com/report/acquired-hemophilia-treatment-market